Literature DB >> 8100631

Dose-dependent intestinal absorption and significant intestinal excretion (exsorption) of the beta-blocker pafenolol in the rat.

H Lennernäs1, C G Regårdh.   

Abstract

The elimination of [3H]pafenolol and metabolites was investigated in fasted and fed rats. Separate groups received intravenous doses (0.3 and 3.0 mumol/kg) and oral doses (1 and 25 mumol/kg). After iv administration of pafenolol, the excretion of unchanged drug into urine and feces was about 50 and 25-30% of the given dose, respectively. The predominating mechanism for the excretion of pafenolol into feces was intestinal excretion (exsorption) directly from blood into gut lumen, since only about 3% of a given iv dose was recovered as pafenolol in the bile. When the oral dose was raised from 1 to 25 mumol/kg, the mean (+/- SD) bioavailability, calculated from urine data, increased from 14 +/- 9 to 30 +/- 11% (P < 0.05) in the starved rats and from 14 +/- 3 to 16 +/- 3% in the fed animals. In parallel, the fraction absorbed from the gut (fa) increased from 19 +/- 9 to 31 +/- 10% in the starved rats and from 16 +/- 4 to 19 +/- 5% in the fed animals, respectively. This indicates that the low bioavailability is due primarily to poor intestinal uptake.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8100631     DOI: 10.1023/a:1018916017723

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  13 in total

1.  Absorption and secretion of monoquaternary ammonium compounds by the isolated intestinal mucosa.

Authors:  K Turnheim; F O Lauterbach
Journal:  Biochem Pharmacol       Date:  1977-01-15       Impact factor: 5.858

2.  Pharmacokinetics of pafenolol after i.v. and oral administration of three separate doses of different strength to man.

Authors:  C G Regardh; A Heggelund; K Kylberg-Hanssen; P Lundborg
Journal:  Biopharm Drug Dispos       Date:  1990-10       Impact factor: 1.627

3.  Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure.

Authors:  K Arimori; M Nakano
Journal:  J Pharmacobiodyn       Date:  1988-07

4.  Transit of pharmaceutical dosage forms through the small intestine.

Authors:  S S Davis; J G Hardy; J W Fara
Journal:  Gut       Date:  1986-08       Impact factor: 23.059

5.  Bile flow and composition during bile acid depletion and administration.

Authors:  C D Klaassen
Journal:  Can J Physiol Pharmacol       Date:  1974-04       Impact factor: 2.273

6.  Single glomerular blood flow as measured with carbonized 141--Ce labelled microspheres.

Authors:  O Källskog; H R Ulfendahl; M Wolgast
Journal:  Acta Physiol Scand       Date:  1972-07

7.  Dose-dependency in the exsorption of theophylline and the intestinal dialysis of theophylline by oral activated charcoal in rats.

Authors:  K Arimori; M Nakano
Journal:  J Pharm Pharmacol       Date:  1988-02       Impact factor: 3.765

8.  Elimination of drugs by active intestinal transport.

Authors:  C F George; B S Gruchy
Journal:  J Pharm Pharmacol       Date:  1979-09       Impact factor: 3.765

9.  Kinetics of the glomerular ultrafiltration in the rat kidney. An experimental study.

Authors:  O Källskog; L O Lindbom; H R Ulfendahl; M Wolgast
Journal:  Acta Physiol Scand       Date:  1975-11

10.  Pharmacokinetics of pafenolol in the rat: a suitable model for studying absorption mechanisms of a drug exhibiting unusual absorption properties in man.

Authors:  H Lenneräs; C G Regårdh
Journal:  Biopharm Drug Dispos       Date:  1990-10       Impact factor: 1.627

View more
  14 in total

1.  Transepithelial transport of diphenhydramine across monolayers of the human intestinal epithelial cell line Caco-2.

Authors:  H Mizuuchi; T Katsura; Y Hashimoto; K Inui
Journal:  Pharm Res       Date:  2000-05       Impact factor: 4.200

2.  A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine.

Authors:  Ophelia Q P Yin; Brian Tomlinson; Albert H L Chow; Moses S S Chow
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 3.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

4.  Population pharmacokinetic analysis of simvastatin and its active metabolite with the characterization of atypical complex absorption kinetics.

Authors:  Seok-Joon Jin; Kyun-Seop Bae; Sang-Heon Cho; Jin-Ah Jung; Unjib Kim; Sangmin Choe; Jong-Lyul Ghim; Yook-Hwan Noh; Hyun-Jung Park; Hee-Sun Kim; Hyeong-Seok Lim
Journal:  Pharm Res       Date:  2014-02-19       Impact factor: 4.200

Review 5.  We may not measure the correct intestinal wall permeability coefficient of drugs: alternative absorptive clearance concept.

Authors:  W L Chiou
Journal:  J Pharmacokinet Biopharm       Date:  1995-06

Review 6.  Drug exsorption from blood into the gastrointestinal tract.

Authors:  K Arimori; M Nakano
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

7.  Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein.

Authors:  J Karlsson; S M Kuo; J Ziemniak; P Artursson
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

8.  Evidence for an interaction between the beta-blocker pafenolol and bile salts in the intestinal lumen of the rat leading to dose-dependent oral absorption and double peaks in the plasma concentration-time profile.

Authors:  H Lennernäs; C G Regårdh
Journal:  Pharm Res       Date:  1993-06       Impact factor: 4.200

9.  Regional gastrointestinal absorption of the beta-blocker pafenolol in the rat and intestinal transit rate determined by movement of 14C-polyethylene glycol (PEG) 4000.

Authors:  H Lennernäs; C G Regårdh
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

10.  The contribution of intestinal secretion to the dose-dependent absorption of celiprolol.

Authors:  S M Kuo; B R Whitby; P Artursson; J A Ziemniak
Journal:  Pharm Res       Date:  1994-05       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.